Management of metastatic germ cell tumors

Expert Review of Anticancer Therapy

Volumn 8, Issue 5, 2008, Pages 771-784

  Hussain, Syed A ^a   Ma, Yuk Ting ^b   Cullen, Michael H ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bleomycin; Carboplatin; Chemotherapy; Cisplatin; Curative chemotherapy; Etoposide; Germ cell tumor; High dose; Prognostic factors

Indexed keywords

APREPITANT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; LEVOFLOXACIN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; SEROTONIN 3 ANTAGONIST; TAXANE DERIVATIVE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ABDOMINAL CRAMP; ADVANCED CANCER; ANOREXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; GERM CELL TUMOR; HEALTH CARE DELIVERY; HEALTH EDUCATION; HUMAN; LUNG FIBROSIS; LUNG TOXICITY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; SEMINOMA; SEPSIS; TESTIS NONSEMINOMA CANCER; MALE; PATHOLOGY; SALVAGE THERAPY; TESTIS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GERMINOMA; HUMANS; MALE; PROGNOSIS; SALVAGE THERAPY; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 45849143303     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.5.771     Document Type: Review

References (72)

1. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J. Urol. 170, 5-11 (2003).
2. Einhorn LH. Treatment of testicular cancer: a new and improved model. J. Clin. Oncol. 8, 1777-1781 (1990).
3. Bosl GJ, Geller NL, Cirrincione C et al. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res. 43, 3403-3407 (1983).
4. Medical Research Council Working Party on Testicular Tumours. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Lancet 1, 8-11 (1985).
5. Birch R, Williams S, Cone A et al. Prognostic factors for favourable outcome in disseminated germ cell tumours. J. Clin. Oncol. 4, 400-407 (1986).
6. Stoter G, Sylvester R, Sleijfer DT et al. Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from an EORTC multi-institutional Phase III study. Cancer Res. 47, 2714-2718 (1987).
7. Droz JP, Kramar A, Ghosn M et al. Prognostic factors in advanced nonseminomatous testicular cancer. Cancer 62, 564-568 (1988).
8. Mead GM, Stenning SP, Parkinson MC et al. The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumours. J. Clin. Oncol. 10, 85-94 (1992).
9. IGCCCG. International Germ Cell Consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 15, 594-603 (1997).
10. Einhorn LH, Donohue JP. Combination chemotherapy with cisdiammine-dichloroplatinum, vinblastine, and bleomycin in disseminated testicular cancer. Ann. Intern. Med. 87, 293-298 (1977).
11. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumours with cisplatin, bleomycin, and either vinblastine or etoposide. N. Eng. J. Med. 316, 1435-1440 (1987).
12. Einhorn LH, Williams SD, Loehrer PJ et al. Evaluation of optimal duration of chemotherapy in favourable-prognosis disseminated germ cell tumours: a Southeastern Cancer Study Group protocol. J. Clin. Oncol. 7, 387-391 (1989).
13. Bosl GJ, Geller NL, Bajorin D et al. A randomised trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumours. J. Clin. Oncol. 6, 1231-1238 (1988).
14. De Wit R, Storer G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J. Clin. Oncol. 15, 1837-1843 (1997).
15. Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favourable-prognosis disseminated germ cell tumours: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 13, 470-476 (1995).
16. Einhorn LH, Foster RS. Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumours: is there a preferred regimen? J. Clin. Oncol. 24, 2597-2598 (2006).
17. Toner GC, Stockler MR, Boyer MJ et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Lancet 357, 739-745 (2001).
18. De Wit R, Roberts T, Wilkinson PM et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J. Clin. Oncol. 19, 1629-1640 (2001).
19. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin verus etoposide and carboplatin in patients with good risk germ cell tumours: a multiinstitutional study. J. Clin. Oncol. 11, 598-606 (1993).
20. Horwich A, Sleijfer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J. Clin. Oncol. 15, 1844-1852 (1997).
21. Bokemeyer C, Kohrmann O, Tischler J et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumours. Ann. Oncol. 7, 1015-1021 (1996).
22. Van Dijk MR, Steyerberg EW, Habbema DF. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: an update based on meta-analysis. Eur. J. Cancer 42, 820-826 (2006).
23. Nichols CR, Williams SD, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumours: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J. Clin. Oncol. 9, 1163-1172 (1991).
24. Wheeler B, Loehrer P, Williams S et al. Ifosfamide in refractory male germ cell tumours. J. Clin. Oncol. 4, 28-34 (1986).
25. Motzer R, Cooper K, Geller N et al. The role of cisplatin + ifosfamide based chemotherapy as salvage therapy for patients with refractory germ cell tumours. Cancer 66, 2476-2482 (1992).
26. Motzer RJ, Geller NL, Tan CC et al. Salvage chemotherapy for patients with germ cell tumours: the Memorial Sloan-Kettering Cancer Centre experience 1979-1989. Cancer 67, 1305-1310 (1991).
27. Nichols CR, Catalano PJ, Crawford D et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumours: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J. Clin. Oncol. 16, 1287-1293 (1998).
28. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann. Oncol. 7, 31-34 (1997)
29. De Wit R, Louwerens M, De Mulder PH et al. Management of intermediate-prognosis germ cell cancer: results of a Phase I/II study of Taxol-BEP. Int. J. Cancer 83, 831-833 (1999).
30. De Wit R, Stoter G, Sleijfer DT et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br. J. Cancer 71, 1311-1314 (1995).
31. Newlands ES, Begent RH, Rustin GJ, Parker D, Bagshawe KD. Further advances in the management of malignant teratomas of the testis and other sites. Lancet 1, 948-951 (1983).
32. Bower M, Newlands ES, Holden L, Rustin GJ, Begent RH. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ ACE chemotherapy. Ann. Oncol. 8, 477-483 (1997).
33. Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumour: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J. Clin. Oncol. 16, 692-701 (1998).
34. Fosså SD, Paluchowska B, Horwich A et al. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br. J. Cancer 93, 1209-1214 (2005).
35. Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell fescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumours. J. Clin. Oncol. 25, 247-256 (2007).
36. Hinton S, Catalano PJ, Einhorn LH et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumours: final analysis of an Intergroup trial. Cancer 97, 1869-1875 (2003).
37. Horwich A, Oliver RTD, Wilkinson PM et al. A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br. J. Cancer 83, 1623-1629 (2000).
38. Clemm C, Bokemeyer C, Gerl A et al. Randomized trial comparing cisplatin/etoposide/ifosfamide with carboplatin monotherapy in patients with advanced metastatic seminoma. Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 1283).
39. Horwich A, Dearnaley GM, Duchesne GM et al. Simple non-toxic treatment of advanced metastatic seminoma with carboplatin. J. Clin. Oncol. 7, 1150-1156 (1989).
40. Schmoll H, Harstrick A, Bokemeyer C et al. Single-agent carboplatin for advanced seminoma: a Phase II study. Cancer 72, 237-243 (1993).
41. Bokemeyer C, Kollmannsberger C, Stenning S et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br. J. Cancer 91, 683-687 (2004).
42. McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide- and cisplatin containing chemotherapy as first-line salvage therapy in germ cell tumours: response and survival. J. Clin. Oncol. 15, 2559-2563 (1997).
43. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumour. J. Clin. Oncol. 16, 2500-2504 (1998).
44. Fossa SD, Stenning SP, Gerl A et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br. J. Cancer 80, 1392-1399 (1999).
45. Motzer RJ, Sheinfeld J, Mazumdar M et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J. Clin. Oncol. 18, 2413-2418 (2000).
46. Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumours. J. Clin. Oncol. 23, 6549-6555 (2005).
47. Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumour activity in patients with previously treated germ cell tumours. J. Clin. Oncol. 12, 2277-2283 (1994).
48. Mead GM, Cullen MH, Huddart R et al. A Phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br. J. Cancer 93, 178-184 (2005).
49. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumours. J. Clin. Oncol. 17, 509-511 (1999).
50. Bokemeyer C, Geri A, Schöffski P et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J. Clin. Oncol. 17, 512-516 (1999).
51. Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J. Clin. Oncol. 20, 2031-2037 (2002).
52. Hinton S, Catalano P, Einhorn LH et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumours (E9897). J. Clin. Oncol. 20, 1859-1863 (2002).
53. Kollmannsberger C, Beyer J, Liersch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensely pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J. Clin. Oncol. 22, 108-114 (2004).
54. Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumour patients: a Phase II study. Eur. Urol. 46, 216-222 (2004).
55. Broun ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumours treated with high-dose chemotherapy and autologous bone marrow rescue. Ann. Intern. Med. 117, 124-128 (1992).
56. Motzer RJ, Mazumdar M, Bosl GJ et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumours: treatment results and prognostic factors for survival and toxicity. J. Clin. Oncol. 14, 1098-1105 (1996).
57. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumours: a multivariate analysis of prognostic variables. J. Clin. Oncol. 14, 2638-2645 (1996).
58. Bhatia S, Abonour R, Porcu P et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J. Clin. Oncol. 18, 3346-3351 (2000).
59. Pico JL, Rosti G, Kramar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann. Oncol. 16, 1152-1159 (2005).
60. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumour patients. J. Clin. Oncol. 18, 1173-1180 (2000).
61. Beyer J, Schwella N, Zingsem, I et al. Hematopoietic rescue after high-dose chemotherapy sing autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J. Clin. Oncol. 13, 1328-1335 (1995).
62. Baniel J, Foster RS, Gonin R et al. Late relapse of testicular cancer. J. Clin. Oncol. 13, 1170-1176 (1995).
63. Gerl A, Clemm C, Schmeller N et al. Late relapse of germ cell tumours after cisplatin-based chemotherapy. Ann. Oncol. 8, 41-47 (1997).
64. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumours: current concepts and controversies. Semin. Urol. Oncol. 20, 262-271 (2002).
65. Stephenson AJ, Sheinfeld J. The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urol. Oncol. 22, 225-235 (2004).
66. Horwich A, Paluchowska B, Norman A et al. Residual mass following chemotherapy of seminoma. Ann. Oncol. 8, 37-40 (1997).
67. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100, 228-237 (2004).
68. Cullen MH, Billingham LJ, Gaunt CH, Steven NJ. Rational selection of patients for antibacterial prophylaxis following chemotherapy. J. Clin. Oncol. 25, 4821-4828 (2007).
69. Fossa SD, Kaye SB, Mead GM et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. J. Clin. Oncol. 16, 716-724 (1998).
70. Leibovici L, Paul M, Cullen MH et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107(8), 1743-1751 (2006).
71. Kris MG, Hesketh PJ, Somerfield MR et al. American society of clinical oncology guideline for antiemetics in oncology: update 2006. J. Clin. Oncol. 24, 2932-2947 (2006).
72. Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter? Lancet 341, 999-1002 (1993).